Belgium's leading life sciences research institute, spanning immunology, neuroscience, plant biology, and structural biology with strong EU project leadership.
VIB is the Flanders Institute for Biotechnology, one of Belgium's premier life sciences research centres. They conduct fundamental and translational research across immunology, neuroscience, plant biology, structural biology, and cancer, with a strong track record of translating discoveries toward clinical and agricultural applications. Their work spans from molecular mechanisms (protein aggregation, cell death pathways, endothelial metabolism) to disease-oriented research in neurodegeneration, inflammatory disorders, and crop improvement. With 126 H2020 projects and over €86 million in EU funding, they function as both a research powerhouse and a training hub for early-career scientists through extensive MSCA and ERC programmes.
Extensive work on dendritic cells, Kupffer cells, macrophages, tissue-resident immune cells, and inflammatory diseases including asthma, allergy, and IBD (projects: KCs and Gut Antigens, Tissue-Tregs, ENVIROIMMUNE, PIBD-SETQuality, FMF-Dia).
Research on synaptic maintenance, protein aggregation in neurodegeneration, Alzheimer's disease mechanisms, and neural circuit function (projects: RobustSynapses, HEALTHYSYNAPSES, MANGO, AD-gut, AD-VIP, SorCSbalance).
Work on programmed cell death in plants, clathrin-mediated endocytosis, drought resistance, maize genetics, and reverse genetics approaches (projects: PROCELLDEATH, T-Rex, EMPHASIS-PREP).
Nanobody-enabled structural studies, bacterial amyloid secretion, protein complex characterisation, and protein crystallization (projects: NESIAC, BAS-SBBT, EPIC, MANGO).
Breast cancer risk stratification, tumour immunology, biomarker discovery, and immunocytokine development (projects: B-CAST, AcTafactors, with recent keyword emphasis on cancer and biomarkers).
Spatial metabolomics, life science data infrastructure, genome editing tools, and multi-omics integration (projects: METASPACE, ELIXIR-EXCELERATE, MULTIMOT).
In their earlier H2020 period (2015–2018), VIB's work was broadly distributed across structural biology, bioinformatics, microbiome research, algal biotechnology, and drought-resistant crops — reflecting a wide-ranging fundamental science portfolio. By the later period (2019–2022), the focus sharpened significantly toward immunology and disease mechanisms: liver biology, Kupffer cells, dendritic cells, inflammation, asthma, and allergy became dominant themes, alongside continued plant genetics work (maize, reverse genetics). Multi-omics and biomarker approaches also gained prominence, suggesting a shift from purely fundamental discovery toward more translational, disease-oriented research with stronger clinical relevance.
VIB is concentrating its research toward tissue-specific immunology (especially liver and lung), multi-omics biomarker discovery, and translational crop genetics — expect future projects at the intersection of immune mechanisms and clinical applications.
VIB predominantly leads projects, coordinating 57% of their H2020 portfolio — an unusually high ratio that reflects both their institutional capacity and scientific authority. They operate as a hub organisation with 633 unique consortium partners across 41 countries, indicating they rarely repeat the same partnerships and instead build project-specific teams. Their heavy use of individual fellowships (MSCA-IF: 22 projects) and ERC grants (COG: 16, POC: 9) means many projects are PI-driven with small teams, while their RIA participation (33 projects) demonstrates equal comfort in large multi-partner consortia.
VIB has built one of the largest collaboration networks among European research centres, with 633 unique partners spanning 41 countries. Their partnerships are geographically pan-European with no strong regional bias, reflecting their status as a go-to life sciences collaborator for institutions across the continent.
VIB combines the depth of a focused research institute with the breadth of a university system — maintaining world-class groups in immunology, neuroscience, plant biology, and structural biology under one roof. Their nanobody technology heritage (originating from VUB/VIB collaborations) gives them unique capabilities in protein engineering and structural studies. For consortium builders, VIB offers both scientific leadership and a proven track record of managing EU projects, making them an exceptionally reliable coordinator choice in life sciences.
